For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,131,444 | 3,724,755 | ||
| General and administrative | 1,898,397 | 2,348,227 | ||
| Total operating expenses | 4,029,841 | 6,072,982 | ||
| Loss from operations | -4,029,841 | -6,072,982 | ||
| (loss) gain on remeasurement of warrant liabilities | -27,816 | 11,126 | ||
| Interest expense | 2,605 | 4,797 | ||
| Interest income | 59,103 | 22,847 | ||
| Other expense, net | -6,774 | -1,850 | ||
| Total other income, net | 21,908 | 27,326 | ||
| Loss before provision for income taxes | -4,007,933 | -6,045,656 | ||
| Provision for income taxes | 2,840 | 7,954 | ||
| Net loss | -4,010,773 | -6,053,610 | ||
| Basic EPS | -0.06 | -0.12 | ||
| Basic Average Shares | 72,685,740 | 49,847,872 | ||
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)